about
Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4DLong-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression.Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation.Focal fat masquerading as malignancy in the liver graft of a post-transplant patient.New-Onset Diabetes Mellitus After Transplantation in a Cynomolgus Macaque (Macaca fasicularis).New-onset diabetes after liver transplantation: from pathogenesis to management.Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy.New-Onset Diabetes Mellitus Associated with Sirolimus Use in Renal Transplant Recipients.Nonalcoholic fatty liver disease and liver transplantation.Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterasesToxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients.Chimerism-based tolerance in organ transplantation: preclinical and clinical studies.Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients.Ethnicity predicts metabolic syndrome after liver transplant.Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients.Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis.Use of new ADA and WHO criteria for the diagnosis of impaired fasting glycemia and diabetes in kidney graft recipients.Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events.Prevalence of gingival overgrowth in transplant patients immunosuppressed with tacrolimus.Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression.Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets.Tacrolimus and angiotensin receptor blockers associated with changes in serum adiponectin level in new-onset diabetes after renal transplantation: single-center cross-sectional analysis.De novo nonalcoholic fatty liver disease after liver transplantation.Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?Cholesterol Metabolism Altered and FGF21 Levels High After Pediatric Liver Transplantation Despite Normal Serum Lipids
P2860
Q34119706-B6877A0D-3378-4C70-AD89-F663391E5C87Q34496604-BEC1EAA7-DF3A-4060-BA7D-1D40397931F8Q35745702-ABC85B89-D156-4161-B076-2DE209E97C01Q35840922-6EA26BAB-4B16-4AF7-A9C5-6481501E0AD1Q35996489-40C31233-0DE6-4B22-9AFF-4ECD7054270FQ36138559-C89E5B11-8043-405E-A0BF-44C723CE5795Q36318218-A431AE4D-9511-4D38-8A27-EB28A477C515Q36319144-AE44BFF1-F194-44FF-8709-5263680E5064Q36429189-450A2DD3-4AA4-4D58-8CBB-B1A4D84CF7CDQ36579585-3245995F-A50E-4D71-BE7B-C111CB2379B0Q37873950-9D01BC57-4AC5-4C64-BC95-4D5A4B135D22Q38212215-DFA0C9DB-0D3E-400E-B695-D71109DD9A7CQ38286355-5AF4BF6C-0F1D-4B87-80BC-77E6486190BCQ39215677-2366D465-5263-4170-913D-92324118358AQ40242723-37763551-A60C-4B58-8877-3E521E9ECB10Q40707126-AC39EE22-1896-4F13-9AFE-016B86104A0FQ41565564-293CC963-0B14-4D05-9A67-E03D973E5189Q42365178-C3D9336B-1796-468B-B71E-C5D5B782A3C5Q44161554-A477939F-BC75-438A-BF47-29C3AAFED217Q44348839-BA3C873F-051B-4FAB-87E5-C1A789A4682FQ44796501-334712EF-1DAD-4F88-B483-B238C0FB9D74Q45962265-04663A42-F9A1-4966-86A0-2A92D72052ACQ45981052-8C095515-A622-4012-9D76-2A7EA5F9C2DFQ46103389-40F3C8DA-5CD8-4945-BB75-DEED89797A16Q46201190-FE963AB6-DBEC-4758-8722-C6B977687503Q46208453-80DDFBB1-C2C7-46DB-99AD-EF4E72CB5DD5Q54661902-C6FA8FED-5D66-4472-8361-5B9546D709AEQ57675055-1F64763B-BC6D-4AA0-B1D2-FC1AD1BDEC76
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
The metabolic effects of cyclosporin and tacrolimus.
@ast
The metabolic effects of cyclosporin and tacrolimus.
@en
The metabolic effects of cyclosporin and tacrolimus.
@nl
type
label
The metabolic effects of cyclosporin and tacrolimus.
@ast
The metabolic effects of cyclosporin and tacrolimus.
@en
The metabolic effects of cyclosporin and tacrolimus.
@nl
prefLabel
The metabolic effects of cyclosporin and tacrolimus.
@ast
The metabolic effects of cyclosporin and tacrolimus.
@en
The metabolic effects of cyclosporin and tacrolimus.
@nl
P2860
P356
P1476
The metabolic effects of cyclosporin and tacrolimus.
@en
P2093
Marchetti P
Navalesi R
P2860
P2888
P304
P356
10.1007/BF03343761
P577
2000-07-01T00:00:00Z
P6179
1049879675